OncoSec Medical (ONCS)
0.28
0.07 (33.21%)
At close: Jun 23, 2023, 8:00 PM
33.21% (1D)
| Bid | n/a |
| Market Cap | 1.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.14M |
| EPS (ttm) | -20.31 |
| PE Ratio (ttm) | -0.013648449039881832 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 51,295,233 |
| Avg. Volume (20D) | 2,131,119 |
| Open | 0.35 |
| Previous Close | 0.21 |
| Day's Range | 0.25 - 0.40 |
| 52-Week Range | 0.18 - 20.46 |
| Beta | 2.00 |
About ONCS
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2010
Employees 40
Stock Exchange NASDAQ
Ticker Symbol ONCS
Website https://oncosec.com